Article
Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2.
Cardiovascular intervention and therapeutics - 1 Oct 2021
Watanabe Hirotoshi, Morimoto Takeshi, Ogita Manabu, Suwa Satoru, Natsuaki Masahiro, Suematsu Nobuhiro, Koeda Yorihiko, Morino Yoshihiro, Nikaido Akira, Hata Yoshiki, Doi Masayuki, Hibi Kiyoshi, Kimura Kazuo, Yoda Shunsuke, Kaneko Takeo, Nishida Koji, Kawai Kazuya, Yamaguchi Koji, Wakatsuki Tetsuzo, Tonoike Norimasa, Yamamoto Masashi, Shimizu Shogo, Shimohama Takao, Ako Junya, Kimura Takeshi
Abstract excerpt
The ultra-short dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy might be promising after percutaneous coronary intervention (PCI). However, CYP2C19 loss-of-function (LOF) alleles have been reported to diminish the effect of clopidogrel, and clopidogrel monotherapy has a concern about the increased ischemic risk for patients with such alleles. STOPDAPT-2 is the multicenter prospective...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.